SAFETY DATA SHEETS

This SDS packet was issued with item:

076207849

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

076207807 076207815 076207823 076207831 076207856

Product: RIVA LIGHT CURE HV CAPSULES

Date / Revised: 20.02.2013

Page 1 of 4

Revision: 3

1. Substance / Preparation and Company name

Product Name:

riva light cure hy capsules

Recommended use:

light-cured dental cement for dental restorations by dental professionals.

Manufacturer / Supplier

SDI Limited

3-13 Brunsdon Street, Bayswater

Victoria, 3153, Australia

SDI Inc.

Telephone:

729 N.Route 83, Suite 315 Bensenville 60106 IL, USA

Telephone:

+61 3 8727 7111 (Business hours)

630 238 8300 (Business hours)

Southern Dental Industries Ltd

Block 8, St Johns Court

Swords Road Santry, Dublin 9, Ireland SDI Brasil Indústria e Comércio Ltda Rua Dr. Virgílio de Carvalho Pinto, 612 Pinheiros, São Paulo, 05415, 030

Pinheiros, São Paulo, 05415-020

Brasil

Telephone:

+353 1 886 9577 (Business Hours)

<u>Telephone</u>:

+55 11 3092 7100 (Business Hours)

Emergency contact number: +61 3 8727 7111

2. Composition / Information on ingredients

Composition:	<u>CAS No.</u>	<u>Wt. %</u>
Compartment 1:		
Polyacrylic Acid Tartaric Acid 2-Hydroxyethyl Methacrylate Dimethacrylate Cross-linker Acidic Monomer	9003-01-4 87-69-4 868-77-9	15-25 1-5 15-25 10-25 10-20
Compartment 2:		
Fluoroaluminosilicate glass powder	-	93-100

3. Hazard Identification

Xi - IRRITANT

Materials in the two compartments are irritants. However, under normal conditions of use, contact with these materials by the user is generally not expected.

Risk Phrases:

36/37/38

Irritating to eyes, respiratory system, and skin.

43

May cause sensitisation by skin contact.

Safety Phrases:

24/25

Avoid contact with skin and eyes.

26

In case of contact with eyes, rinse immediately with plenty of water

and seek medical advice.

28

After contact with skin, wash immediately with water and soap.



MATERIAL SAFETY DATA SHEET [according to GHS and NOHSC:2011(2003)]

Product: RIVA LIGHT CURE HV CAPSULES

Date / Revised: 20.02.2013

Page 2 of 4

Revision: 3

4. First Aid Measures

Eye (contact):

Flush opened eye with running water for at least 5 minutes.

Seek medical

attention.

Skin (contact):

Immediately remove contaminated clothing and wash skin with plenty of water.

If irritation occurs seek medical attention.

Inhalation:

Remove to fresh air. Seek medical attention if irritation develops or if feeling

unwell.

Ingestion:

Immediately drink plenty of water.

Do NOT induce vomiting. Seek medical

attention.

5. Fire Fighting Measures

Suitable extinguishing media:

None required.

Unusual Fire and Explosion

Hazards:

None.

Special protective equipment:

No special protective equipment required.

6. Accidental Release Measures

Personal precautions:

Do not get into eyes, on skin or clothing.

Environmental precautions:

Clear up spillages. Transfer to a container for disposal.

Methods for cleaning up:

Wash the spillage area clean with water.

Handling and storage

<u>Handling</u>

Store sealed containers away from heat and light.

Storage

Storage by the end user (Dental Clinic) is recommended to be at temperatures between 4° - 20° C (39° - 68° F) and should be kept away from direct sunlight.

Distribution

During distribution, to our customers, this product can be transported in non-refrigerated conditions between 15° to 25° C. This product can also withstand temperatures up to 40° C for short periods (2 to 3 days) and intermittent peaks up to 50° C.

8. Exposure controls and personal protection

Respiratory protection:

None required due to product containment and dosage size.

Hand protection:

Rubber, latex or PVC gloves.

Eye protection:

Recommended.

General safety and hygiene measures:

None

Product: RIVA LIGHT CURE HV CAPSULES

Date / Revised: 20.02.2013

Page 3 of 4

Revision: 3

9. Physical and chemical properties

Appearance:

Smooth, pale-coloured paste

Odour:

Slightly characteristic odour

Boiling point:

Approx. 100°C (212°F)

Melting point:

Not applicable

Specific gravity:

2.2 g/cm³

Flash point:

Not applicable

Flammable:

Not flammable

Autoflammability:

Not applicable

Explosive properties:

Does not present an explosion hazard

Oxidizing properties:

Not applicable

Vapour pressure (@ 20°C):

Approx. 23 hPa

Relative density:

<1.0

Solubility:

Miscible

10. Stability and Reactivity

Stability:

Stable under normal conditions.

Conditions to avoid:

Avoid excessive heat

Materials to avoid:

None.

Hazardous decomposition products:

None when used as directed.

Hazardous reactivity (polymerization):

No hazardous reactions known.

11. Toxicological information

Acute toxicity:

Contact with skin and eyes may cause irritation.

Eye (contact):

Irritating to eyes

Skin (contact):

Possible skin irritant

Inhalation:

Not expected due to product containment and dosage size.

Ingestion:

Irritant not likely in small amounts

12. Ecological information

Self assessment:

Not readily biodegradable. Avoid large quantities entering drains, surface water

or ground water.

MATERIAL SAFETY DATA SHEET [according to GHS and NOHSC:2011(2003)]

Product: RIVA LIGHT CURE HV CAPSULES

Date / Revised: 20.02.2013

Page 4 of 4

Revision: 3

13. Disposal considerations

Dispose of in accordance with local official regulations.

14. Transport Information

This product is not considered to be a dangerous good within the meaning of transportation regulations.

15. Regulatory information

This product is regulated by

TGA Medical Devices Directive 93/42/EEC FDA

National regulations

16. Other information

The information contained in the Material Safety Data Sheet is based on data considered to be accurate, however, no warranty is expressed or implied regarding the accuracy of the data or the results to be obtained from the use thereof.

Prepared by: SDI Limited

3-13 Brunsdon Street, Bayswater

Victoria, 3153, Australia

Phone Number:

+61 3 8727 7111

Department issuing MSDS:

Contact:

Research and Development

Operations Director



Riva Light Cure HV Capsules

SDI Limited

Version No: **3.1.1.1**Safety Data Sheet according to OSHA HazCom Standard (2012) requirements

Issue Date: 29/01/2016 Print Date: 24/03/2016 Initial Date: Not Available L.GHS.USA.EN

SECTION 1 IDENTIFICATION

Product Identifier

Product name	Riva Light Cure HV Capsules
Synonyms	Not Available
Other means of identification	Not Available

Recommended use of the chemical and restrictions on use

Relevant identified uses Light-cured dental cement for dental restorations by dental professionals.

Name, address, and telephone number of the chemical manufacturer, importer, or other responsible party

Registered company name	SDI Limited	SDI Brazil Industria E Comercio Ltda	SDI Germany GmbH	
Address	3-15 Brunsdon Street VIC Bayswater 3153 Australia	Rua Dr. Virgilio de Carvalho Pinto, 612 São Paulo CEP 05415-020 Brazil	Hansestrasse 85 Cologne D-51149 Germany	
Telephone	+61 3 8727 7111 (Business Hours)	+55 11 3092 7100	+49 0 2203 9255 0	
Fax	+61 3 8727 7222	+55 11 3092 7101	+49 0 2203 9255 200	
Website	www.sdi.com.au	www.sdi.com.au	www.sdi.com.au	
Email	info@sdi.com.au	brasil@sdi.com.au	germany@sdi.com.au	
Registered company name	SDI (North America) Inc.			
Address	1279 Hamilton Parkway IL Itasca 60143 United States			
Telephone	+1 630 361 9200 (Business hours)			
Fax	Not Available			
Website	Not Available			
Email	USA.Canada@sdi.com.au			

Emergency phone number

Emergency phone number			
Association / Organisation	SDI Limited	Not Available	Not Available
Emergency telephone numbers	+61 3 8727 7111	Not Available	Not Available
Other emergency telephone numbers	ray.cahill@sdi.com.au	Not Available	Not Available
Association / Organisation	Not Available		
Emergency telephone numbers	+61 3 8727 7111		
Other emergency telephone numbers	Not Available		

SECTION 2 HAZARD(S) IDENTIFICATION

Classification of the substance or mixture NFPA 704 diamond



Note: The hazard category numbers found in GHS classification in section 2 of this SDSs are NOT to be used to fill in the NFPA 704 diamond. Blue = Health Red = Fire Yellow = Reactivity White = Special (Oxidizer or water reactive substances)

Classification

Skin Corrosion/Irritation Category 2, Eye Irritation Category 2A, Skin Sensitizer Category 1, Specific target organ toxicity - single exposure Category 3 (respiratory tract irritation)

Version No: **3.1.1.1** Page **2** of **10** Issue Date: **29/01/2016**

Riva Light Cure HV Capsules

Print Date: 24/03/2016

Label elements

GHS label elements



SIGNAL WORD V

WARNING

Hazard statement(s)

H315	Causes skin irritation.
H319	Causes serious eye irritation.
H317	May cause an allergic skin reaction.
H335	May cause respiratory irritation.

Hazard(s) not otherwise specified

Not Applicable

Precautionary statement(s) Prevention

P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P302+P352	IF ON SKIN: Wash with plenty of soap and water.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P304+P340	IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.

Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Precautionary statement(s) Disposal

P501 Dispose of contents/container in accordance with local regulations.

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
		compartment 1 contains
9003-01-4	15-25	acrylic acid homopolymer
868-77-9	15-25	2-hydroxyethyl methacrylate
Not Available	10-25	dimethacrylate cross-linker
Not Available	10-20	acid monomer
87-69-4	1-5	tartaric acid
		compartment 2 contains
Not Available	93-100	glass powder

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret.

SECTION 4 FIRST-AID MEASURES

Description of first aid measures

Eye Contact

If this product comes in contact with the eyes:

- Wash out immediately with fresh running water.
 Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
 - Obtained by Global Safety Management, 1-813-435-5161 www.GSMSDS.com

Version No: 3.1.1.1 Page 3 of 10 Issue Date: 29/01/2016 Print Date: 24/03/2016

Riva Light Cure HV Capsules

	Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	If furnes or combustion products are inhaled remove from contaminated area. Seek medical attention.
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Most important symptoms and effects, both acute and delayed

See Section 11

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 FIRE-FIGHTING MEASURES

Extinguishing media

Foam is generally ineffective.

Special hazards arising from the substrate or mixture

Fire Incompatibility	None known.		
Special protective equipm	Special protective equipment and precautions for fire-fighters		
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water courses. Use water delivered as a fine spray to control fire and cool adjacent area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. 		
Fire/Explosion Hazard	 Combustible. Slight fire hazard when exposed to heat or flame. Heating may cause expansion or decomposition leading to violent rupture of containers. On combustion, may emit toxic fumes of carbon monoxide (CO). May emit acrid smoke. 		

Combustion products include; carbon dioxide (CO2) nitrogen oxides (NOx) other pyrolysis products typical of burning organic materialMay emit poisonous

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

fumes.May emit corrosive fumes.

Minor Spills	 Clean up all spills immediately. Avoid contact with skin and eyes. Wear impervious gloves and safety goggles. Trowel up/scrape up. Place spilled material in clean, dry, sealed container. Flush spill area with water.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

Safe handling

- ► Avoid all personal contact, including inhalation.
- ▶ Wear protective clothing when risk of exposure occurs.

▶ Mists containing combustible materials may be explosive.

Version No: 3.1.1.1 Page 4 of 10 Issue Date: 29/01/2016

Riva Light Cure HV Capsules

Print Date: 24/03/2016

- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- ▶ DO NOT enter confined spaces until atmosphere has been checked.
- DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
- When handling, DO NOT eat, drink or smoke
- ▶ Keep containers securely sealed when not in use.
- Avoid physical damage to containers.
- Always wash hands with soap and water after handling.
- Work clothes should be laundered separately. Launder contaminated clothing before re-use.
- Use good occupational work practice.
- Observe manufacturer's storage and handling recommendations contained within this SDS.
- Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Other information

Store between 5 and 25 deg. C.

Do not store in direct sunlight.

Store in a dry and well ventilated-area, away from heat and sunlight.

Conditions for safe storage, including any incompatibilities

Suitable container

- ▶ DO NOT repack. Use containers supplied by manufacturer only.
- ▶ Check that containers are clearly labelled and free from leaks

Storage incompatibility

None known

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Not Available

EMERGENCY LIMITS

Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
acrylic acid homopolymer	Acrylic acid polymers; (Acrylic polymer or resin)	7.5 mg/m3	83 mg/m3	500 mg/m3
2-hydroxyethyl methacrylate	Hydroxyethyl methacrylate, 2-	0.71 mg/m3	7.8 mg/m3	1000 mg/m3
tartaric acid	Tartaric acid	1.6 mg/m3	17 mg/m3	100 mg/m3
Ingredient	Original IDLH	Revised IDLH		
acrylic acid homopolymer	Not Available	Not Available		
2-bydrovyetbyl methachilate	Not Available	Not Available		

Ingredient	Original IDLH	Revised IDLH
acrylic acid homopolymer	Not Available	Not Available
2-hydroxyethyl methacrylate	Not Available	Not Available
dimethacrylate cross-linker	Not Available	Not Available
acid monomer	Not Available	Not Available
tartaric acid	Not Available	Not Available
glass powder	Not Available	Not Available

MATERIAL DATA

NOTE D: Certain substances which are susceptible to spontaneous polymerisation or decomposition are generally placed on the market in a stabilised form. It is in this form that they are listed on

When they are placed on the market in a non-stabilised form, the label must state the name of the substance followed by the words "non-stabilised"

European Union (EU) List of harmonised classification and labelling hazardous substances, Table 3.1, Annex VI, Regulation (EC) No 1272/2008 (CLP) - up to the latest ATP

Exposure controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.

The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.

Employers may need to use multiple types of controls to prevent employee overexposure.

General exhaust is adequate under normal operating conditions. Local exhaust ventilation may be required in special circumstances. If risk of overexposure

Appropriate engineering controls

exists, wear approved respirator. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. Provide adequate ventilation in warehouses and enclosed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.			
Type of Contaminant:	Air Speed:		
	0.05.05/- /50.400		

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion)	2.5-10 m/s (500-2000 f/min.)

Version No: **3.1.1.1** Page **5** of **10** Issue Date: **29/01/2016**

Riva Light Cure HV Capsules

Print Date: 24/03/2016

ı	Within each range the appropriate value depends on:
- 1	

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 t/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Personal protection











Eye and face protection

Safety glasses with side shieldsChemical goggles.

Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Skin protection S

See Hand protection below

Hands/feet protection

- ► Wear chemical protective gloves, e.g. PVC.
- Wear safety footwear or safety gumboots, e.g. Rubber
- Rubber Gloves

Body protection

See Other protection below

Other protection

- Overalls.P.V.C. apron.
- ▶ Barrier cream.
 - Skin cleansing cream.
 - ► Eye wash unit.

Thermal hazards Not Available

Respiratory protection

 $Type \ A \ Filter \ of sufficient \ capacity. \ (AS/NZS\ 1716\ \&\ 1715, EN\ 143:2000\ \&\ 149:2001, \ ANSI\ Z88\ or\ national\ equivalent)$

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P3	-	A-PAPR-AUS / Class 1 P3
up to 50 x ES	-	A-AUS / Class 1 P3	-
up to 100 x ES	-	A-2 P3	A-PAPR-2 P3 ^

^{^ -} Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Smooth, pale-coloured paste with slightly characteristic odour.		
	,, , , , , , , , , , , , , , , , , , , ,		
Physical state	Non Slump Paste	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available

Version No: 3.1.1.1 Page 6 of 10 Issue Date: 29/01/2016 Print Date: 24/03/2016

Riva Light Cure HV Capsules

Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water (g/L)	Not Available	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on	toxicolor	ical effects
IIIIOI IIIalioii oii	LOXICOIOL	licai ellecis

Information on toxicologic	al effects
Inhaled	Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Acute effects from inhalation of high concentrations of vapour are pulmonary irritation, including coughing, with nausea; central nervous system depression characterised by headache and dizziness, increased reaction time, fatigue and loss of co-ordination
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual.
Skin Contact	Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin

(spongiosis) and intracellular oedema of the epidermis. The material may accentuate any pre-existing dermatitis condition

Open cuts, abraded or irritated skin should not be exposed to this material

Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.

Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.

Chronic

Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.

Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. Sensitisation may give severe responses to very low levels of exposure, in situations where exposure may occur.

Controlled for the properties to the properties to the properties of expectation, in clied above the properties to the properties to the properties to the properties of the properties to the p			
Riva Light Cure HV Capsules	TOXICITY Not Available	IRRITATION Not Available	
acrylic acid homopolymer	TOXICITY	IRRITATION	
acrylic acid nomopolymer	Oral (rat) LD50: 2500 mg/kgd ^[2]	Nil reported	
	TOXICITY	IRRITATION	
2-hydroxyethyl methacrylate	Dermal (rabbit) LD50: >3000 mg/kg ^[1]	* Rohm & Haas	
	Oral (rat) LD50: >4000 mg/kg ^[1]	Eye (rabbit): SEVERE *	
		post-exposure	
		Skin (rabbit): non-irritating*	
	TOXICITY	IRRITATION	
tartaric acid	dermal (rat) LD50: >2000 mg/kg ^[1]	Nil reported	
	Oral (rat) LD50: ca.920 mg/kg ^[1]		
glass powder	TOXICITY	IRRITATION	
	Not Available	Not Available	
Legend:	Value obtained from Europe ECHA Registered Substances - Acute toxici	ty 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data	

Version No: **3.1.1.1** Page **7** of **10** Issue Date: **29/01/2016**

Riva Light Cure HV Capsules

Print Date: 24/03/2016

extracted from RTECS - Register of Toxic Effect of chemical Substances

ACRYLIC ACID

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production. The substance is classified by IARC as Group 3:

NOT classifiable as to its carcinogenicity to humans.

Evidence of carcinogenicity may be inadequate or limited in animal testing.

The following information refers to contact allergens as a group and may not be specific to this product.

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

2-HYDROXYETHYL METHACRYLATE

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production. Where no "official" classification for acrylates and methacrylates exists, there has been cautious attempts to create classifications in the absence of contrary evidence. For example

Monalkyl or monoarylesters of acrylic acids should be classified as R36/37/38 and R51/53

Monoalkyl or monoaryl esters of methacrylic acid should be classified as R36/37/38

Based on the available oncogenicity data and without a better understanding of the carcinogenic mechanism the Health and Environmental Review Division (HERD), Office of Toxic Substances (OTS), of the US EPA previously concluded that all chemicals that contain the acrylate or methacrylate moiety (CH2=CHCOO or CH2=C(CH3)COO) should be considered to be a carcinogenic hazard unless shown otherwise by adequate testing. This position has now been revised and acrylates and methacrylates are no longer *de facto* carcinogens.

Dermal (rabbit): >5000 mg/kg* Effects persist beyond 21 days

TARTARIC ACID

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production. Convulsions, haemorrhage recorded.

Acute Toxicity	0	Carcinogenicity	0
Skin Irritation/Corrosion	✓	Reproductivity	0
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	0
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	0
Mutagenicity	0	Aspiration Hazard	0

Legend:

🗶 – Data available but does not fill the criteria for classification

✓ – Data required to make classification available

Data Not Available to make classification

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

Ingredient	Endpoint	Test Duration (hr)	Species	Value	Source
acrylic acid homopolymer	EC50	384	Crustacea	389.869mg/L	3
acrylic acid homopolymer	EC50	96	Algae or other aquatic plants	8596.446mg/L	3
acrylic acid homopolymer	LC50	96	Fish	1684.686mg/L	3
2-hydroxyethyl methacrylate	LC50	96	Fish	>100mg/L	2
2-hydroxyethyl methacrylate	EC50	48	Crustacea	210mg/L	2
2-hydroxyethyl methacrylate	EC50	504	Crustacea	90.1mg/L	2
2-hydroxyethyl methacrylate	NOEC	504	Crustacea	24.1mg/L	2
2-hydroxyethyl methacrylate	EC50	72	Algae or other aquatic plants	345mg/L	2
tartaric acid	EC50	96	Algae or other aquatic plants	434.65983mg/L	3
tartaric acid	LC50	96	Fish	>100mg/L	2

Version No: 3.1.1.1 Page 8 of 10 Issue Date: 29/01/2016 Print Date: 24/03/2016

Riva Light Cure HV Capsules

Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

tartaric acid	EC50	48	Crustacea	93.313mg/L	2
tartaric acid	EC50	72	Algae or other aquatic plants	51.4043mg/L	2
tartaric acid	NOEC	72	Algae or other aquatic plants	3.125mg/L	2
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) -				

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
acrylic acid homopolymer	LOW	LOW
2-hydroxyethyl methacrylate	LOW	LOW
tartaric acid	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
acrylic acid homopolymer	LOW (LogKOW = 0.4415)
2-hydroxyethyl methacrylate	LOW (BCF = 1.54)
tartaric acid	LOW (LogKOW = -1.0017)

Mobility in soil

Ingredient	Mobility
acrylic acid homopolymer	HIGH (KOC = 1.201)
2-hydroxyethyl methacrylate	HIGH (KOC = 1.043)
tartaric acid	HIGH (KOC = 1)

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods

Product / Packaging disposal

- ▶ DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- ▶ Where in doubt contact the responsible authority.

Consult State Land Waste Management Authority for disposal.

Bury residue in an authorised landfill.

SECTION 14 TRANSPORT INFORMATION

Labels Required

Marine Pollutant NO

Land transport (DOT): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

ACRYLIC ACID HOMOPOLYMER(9003-01-4) IS FOUND ON THE FOLLOWING REGULATORY LISTS

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

2-HYDROXYETHYL METHACRYLATE(868-77-9) IS FOUND ON THE FOLLOWING REGULATORY LISTS

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

US Toxic Substances Control Act (TSCA) - Premanufacture Notice (PMN) Chemicals

TARTARIC ACID(87-69-4) IS FOUND ON THE FOLLOWING REGULATORY LISTS

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

GLASS POWDER(NOT APPLICABLE) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Not Applicable

Federal Regulations

Version No: **3.1.1.1** Page **9** of **10** Issue Date: **29/01/2016**

Riva Light Cure HV Capsules

Print Date: 24/03/2016

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SECTION 311/312 HAZARD CATEGORIES

Immediate (acute) health hazard	YES
Delayed (chronic) health hazard	NO
Fire hazard	NO
Pressure hazard	NO
Reactivity hazard	NO

US. EPA CERCLA HAZARDOUS SUBSTANCES AND REPORTABLE QUANTITIES (40 CFR 302.4)

None Reported

State Regulations

US. CALIFORNIA PROPOSITION 65

None Reported

National Inventory	Status
Australia - AICS	Υ
Canada - DSL	Υ
Canada - NDSL	N (acrylic acid homopolymer; tartaric acid; 2-hydroxyethyl methacrylate)
China - IECSC	Υ
Europe - EINEC / ELINCS / NLP	N (acrylic acid homopolymer)
Japan - ENCS	Υ
Korea - KECI	Υ
New Zealand - NZIoC	Υ
Philippines - PICCS	Υ
USA - TSCA	Υ
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by SDI Limited using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

 ${\sf PC-TWA: Permissible \ Concentration-Time \ Weighted \ Average}$

 ${\sf PC-STEL} : {\sf Permissible \ Concentration-Short \ Term \ Exposure \ Limit}$

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit $_{\circ}$

IDLH: Immediately Dangerous to Life or Health Concentrations

OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level

LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value

LOD: Limit Of Detection

OTV: Odour Threshold Value

BCF: BioConcentration Factors

BEI: Biological Exposure Index

The information contained in the Safety Data Sheet is based on data considered to be accurate, however, no warranty is expressed or implied regarding the accuracy of the data or the results to be obtained from the use thereof.

Other information:

Prepared by: SDI Limited

3-15 Brunsdon Street, Bayswater Victoria, 3153, Australia

Phone Number: +61 3 8727 7111

Date of preparation/revision: 23rd September 2015 Department issuing SDS: Research and Development

Contact: Technical Director

Other information:

Prepared by: SDI Limited

3-15 Brunsdon Street, Bayswater Victoria, 3153, Australia

Phone Number: +61 3 8727 7111

Date of preparation/revision: 23rd September 2015

Version No: 3.1.1.1 Page 10 of 10 Issue Date: 29/01/2016 Print Date: 24/03/2016

Riva Light Cure HV Capsules

Department issuing SDS: Research and Development

Contact: Technical Director